ReviewCurrent pharmaceutical design2014
Treating Arterial Stiffness in Young and Elderly Patients with the Metabolic Syndrome.
Review in Current pharmaceutical design, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02887677 (A Study of the Effects of Dapagliflozin on Ambulatory Aortic Pressure, Arterial Stiffness and Urine Albumin Excretion in Patients With Type 2 Diabetes), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study of the Effects of Dapagliflozin on Ambulatory Aortic Pressure, Arterial Stiffness and Urine Albumin Excretion in Patients With Type 2 Diabetes
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
- Serum adipokine levels in patients with type 1 diabetes are associated with degree of obesity but only resistin is independently associated with atherosclerosis markers.Hormones (Athens, Greece) · 2022Article
- Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.World journal of gastroenterology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arterial stiffness is independently associated with increased cardiovascular risk in patients with cardiovascular risk factors and in the general population. Metabolic syndrome (MetS) is frequently characterized by increased arterial stiffness since all components of MetS are implicated in the pathogenesis of arterial stiffness. We review the management of arterial stiffness in patients with MetS. Several small, short-term studies showed that lifestyle changes, antidiabetic, antihypertensive and lipid-lowering agents improve arterial elasticity. However, differences appear to exist between different classes of agents, with statins and inhibitors of the renin-angiotensin-aldosterone system having the more favorable effects on arterial stiffness. A multifactorial approach appears to be the optimal management of increased arterial stiffness in patients with MetS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.